A case report of HIV-1 superinfection in an HIV controller leading to loss of viremia control: a retrospective of 10 years of follow-up

Diogo Gama Caetano, Fernanda Heloise Côrtes, Gonzalo Bello, Suwellen Sardinha Dias de Azevedo, Brenda Hoagland, Larissa Melo Villela, Beatriz Grinsztejn, Valdiléa Gonçalves Veloso, Monick Lindenmeyer Guimarães and Mariza Gonçalves Morgado

Abstract

Background: HIV controllers (HICs) are a rare group of HIV-1-infected individuals able to naturally control viral replication. Several studies have identified the occurrence of HIV dual infections in seropositive individuals leading to disease progression. In HICs, however, dual infections with divergent outcomes in pathogenesis have been described.

Case presentation: Here, we present a case report of a HIC diagnosed in late 1999 who displayed stable CD4+ T cell levels and low plasmatic viral load across 12 years of follow-up. In early 2013, the patient started to present an increase in viral load, reaching a peak of 10,000 copies/ml in early 2014, followed by an oscillation of viremia at moderate levels in the following years. The genetic diversity of env proviral quasispecies from peripheral blood mononuclear cells (PBMCs) was studied by single genome amplification (SGA) at six timepoints across 2009–2017. Phylogenetic analyses of env sequences from 2009 and 2010 samples showed the presence of a single subtype B variant (called B1). Analyses of sequences from 2011 and after revealed an additional subtype B variant (called B2) and a subsequent dominance shift in the proviral quasispecies frequencies, with the B2 variant becoming the most frequent from 2014 onwards. Latent syphilis related to unprotected sexual intercourse was diagnosed a year before the first detection of B2, evidencing risk behavior and supporting the superinfection hypothesis. Immunologic analyses revealed an increase in CD8+ and CD4+ T cell immune activation following viremia increase and minor T cell subset alterations during follow-up. HIV-specific T cell responses remained low throughout the follow-up period.

Conclusions: Altogether, these results show that loss of viremia control in the HIC was associated with superinfection. These data alert to the negative consequences of reinfection on HIV pathogenesis, even in patients with a long history of viremia control and an absence of disease progression, reinforcing the need for continued use of adequate prevention strategies.

Keywords: HIV-1, HIV-controllers, LTNP, Superinfection, Dual infection
Background
HIV controllers (HICs) are a rare group of HIV-1-infected individuals able to naturally control viral replication. A fraction of those individuals is also classified as long term nonprogressors (LTNP), as they maintain CD4+ T cell counts > 500 cells/mm³ during more than 10 years of infection without progressing to AIDS in the absence of antiretroviral treatment [1].

An aspect of HIV infection is the possibility of infections by two or more phylogenetically distinct and unrelated variants in a single individual, characterizing a dual infection (DI). More specifically, these DIs are classified as coinfections when all variants are concomitantly acquired in a single transmission event or superinfections (SI) when the viruses originate from multiple subsequent transmission events [2]. HIV DI has been described in several studies with significant prevalence mainly among key populations [3–7] and is related to a faster progression to AIDS [8–10]. DIs were also observed among LTNP and/or HIC [11–15], with variable consequences on HIV pathogenesis. While some individuals retain spontaneous disease control [11–13], others present loss of viremia control and experience disease progression [11, 14, 15].

Here, we report the case of an HIV-1 positive individual with natural control of viral replication and no progression to AIDS over more than 10 years of clinical follow-up who presented a partial loss of viremia control after an SI event.

Case presentation
Subject VC06 is a 40-year-old, transgender woman from Rio de Janeiro, Brazil, who was diagnosed with HIV-1 infection at the end of 1999 and has been seen for routine clinical follow-up at the Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil since 2005. In 2009, VC06 signed an informed consent and was enrolled in the INI-Fiocruz LTNP/HIC cohort study, approved by the Brazilian National Human Research Ethics Committee (CONEP 840/2008) and by the FIOCRUZ Research Ethics Committee (CEP 1717.0.000.009–07). Due to study enrollment, individual VC06 was followed at least once every 6–12 months to perform specific infection-monitoring tests (such as HIV-1 RNA viral load quantification and CD4+ T cell counts) and routine clinical laboratory exams and to assess data related to clinical status and exposure to sexually transmitted infections. In addition, blood was collected at each visit to isolate plasma, whole blood and peripheral blood mononuclear cell (PBMC) samples for study. Subject VC06 was initially classified as an LTNP HIV viremic controller (<2000 cp/ml dually infected with two HIV-1 subtype B viruses (de Azevedo et al. 2017) [16]. She carries a nonprotective HLA-B genotype (HLA-B*15:01/ B*48:02) but has heterozygosis for the CCR5-Δ32 mutation, which is considered a host-protective allele for disease infection and progression.

Subject VC06 displayed low-level viremia (<500 copies/ml) in the absence of antiretroviral therapy until early 2013, when she started to show increases in the viral load, reaching approximately 10,000 copies/ml 1 year later (Fig. 1, V92014). The following months were associated with a spontaneous decrease in viral load, reaching 577 copies/ml in August 2015. Combination antiretroviral therapy (cART) with a scheme containing TDF, 3TC, and EFZ was prescribed in November 2015 but interrupted 1 month later by the patient due to intense dizziness related to the treatment. Side effects ceased, but the continuity of the therapy was refused by the patient in the following years. Transient recovery of viremia control was followed by intermittent viral loads above 2000 copies/ml and a new peak of approximately 8000 copies/ml in May 2017. This new peak of viremia was followed by a spontaneous decrease in viral load, reaching 1435 copies/ml in May 2018. The most recent available data indicated a viral load of approximately 3500 copies/ml at the end of 2018 (Fig. 1). Despite increasing viremia, CD4+ T cell counts during the whole period were stable at high levels, suggesting no immunological commitment or disease progression.

In addition to the intermittence of the plasmatic viral load after a controller period, individual VC06 was diagnosed with latent syphilis in May 2010 based on positive VDRL results (1/32) in the absence of clinical signs or symptoms and a previous negative VDRL test in December 2009. The syphilis diagnosis coincided with unprotected sexual intercourse reported by the patient, and treatment with weekly benzathine benzylpenicillin 1,200,000 IU intramuscular injections were administered for 3 weeks starting in November 2010. Late latent syphilis was further diagnosed again at two additional time-points: first in September 2015, based on VDRL titer of 1/8; second in November 2017, based on TPHA positive and a VDRL titer of 1/512. Both cases were preceded by a VDRL titer of 1/1 6 months before and were treated, as described above, in November 2015 and May 2018, respectively. No clinical signs or symptoms associated with syphilis infection were observed during follow-up. Another clinical event during the follow-up period included the diagnosis of an anal fistula at the beginning of 2014, which was surgically treated in the same year.

To assess the patterns of intrahost viral evolution and to investigate the cause associated with the loss of viremia control, PBMCs (1 × 10⁷ cells) from selected visits (Fig. 1) were thawed and used for genomic DNA extraction, as previously described [17]. The genomic DNA obtained was used for amplification by nested PCR single genome amplification
(SGA) and sequencing of a ≈ 600 bp C2-C4 fragment of HIV-1 env, as previously described [18]. A neighbor-joining phylogenetic tree containing all sequences obtained from samples collected over time is shown in Fig. 2. Env sequences from 2009 (V12009; n = 29) and 2010 (V32010; n = 43) samples showed the presence of a single subtype B variant (called B1). Analysis of env sequences from 2011 (V42011; n = 32), 1 year after the diagnosis of syphilis infection, showed the presence of a second subtype B variant (called B2) in addition to the previous B1 variant. These variants branched separately and displayed a mean env genetic distance of 16.8%. Tropism analyses, realized through Geno2pheno tool using a false-positive rate (FPR) of 10% [19], of env sequences, obtained at all time points, showed that both B1 and B2 variants correspond to R5-tropic viruses that present different predominant motifs at the top of the V3 loop (QPGR/QPGG for B1 and GPGR for B2). Env analyses of samples from subsequent time points revealed a shift in the proviral quasispecies proportion, with an increase of B2 variant frequency from 16% in 2011 (V42011; n = 32) to 93% in 2014 (V92014; n = 27). The majority of the B2 (93%) viral quasispecies was maintained even after the reduction of plasmatic viral load in 2016 (V142016; n = 14) as well as after a new peak of viremia (75%) in 2017 (V162017; n = 12) (Fig. 2). For B2 quasispecies from all timepoints (n = 52), 80% of the sequences obtained were classified as R5 with FPR values greater than 45%, while the remaining presented FPR values between 11.5% and 18.5%.

Plasma sequences were obtained from the V92014 and V162017 samples, as previously described [18], supporting that B2 was the replicating variant accounting for the increase in viremia observed at both time points (Fig. 2). Moreover, the distribution of B2 sequences on the env phylogenetic tree indicates a pattern of increasing divergence along the follow-up period, with the identification of two distinct clusters harboring most sequences for the V92014 and V162017 samples. In additional analyses, all B2 sequences were used for estimation and reconstruction of the most recent common ancestor (MRCA), using the Phylip package [20]. The mean genetic distance between the MRCA and the B2 sequences for each visit was calculated to determine B2 viral divergence during follow-up. We observed increasing values of divergence during follow-up (0.9% for V42011, 1.7% for V92014; 3.5% for V142016; 4.4% for V162017), indicating a temporal evolution pattern. These results, in addition to the observation that sequences from the V142016 samples were distributed between the V92014 and V162017 clusters, with no clear predominance of any population, also indicate that different B2-related viral quasispecies accounted for the viral replication in each viremia peak.

To better characterize the SI and assess the divergence between B1 and B2 at a more conserved region of the
viral genome, we conducted SGA of the *int* region from the V42011 sample, in which we first detected the B2 variant, and from the V92014 sample, in which B2 became the dominant variant. A neighbor-joining phylogenetic tree containing the *int* sequences is shown in Fig. 3. In the V42011 sample (obtained at the time of SI detection), a single *int* variant related to B1 was found despite the detection of two variants in the *env* analysis from the same time point. The absence of a second *int* variant is probably related to the low number of sequences obtained at this time point (12 sequences for *int* vs 32 sequences for *env*). In the V92014 sample, however, we identified two *int* variants with a mean genetic distance of 4.2%. Although these data indicate the presence of B1 and B2, the frequencies of both *int* variants differ from those observed for *env* (40% vs 7% for B1; 60% vs 93% for B2). Even though different fragments have distinct PCR efficiencies, which could introduce a bias factor, the
great divergence of representation could be indicative of recombination between \textit{int} and \textit{env} genes.

Finally, to evaluate viral integrity, we obtained the full-length HIV-1 genome from the V1 2009 sample, as previously described [21]. The overlapping fragment sequences obtained allowed the identification of the B$_1$ variant full-length genome and the absence of deletions or frame-shift alterations related to genetic defects, indicating that B$_1$ is a replication-competent virus. The full-length B$_1$ genome also confirmed that the \textit{int} variants obtained via SGA of the V4 2011 sample are related to this variant (Fig. 3). Isolation of the full-length genome for the B$_2$ variant was not possible due to the equivalent frequencies of B$_1$ and B$_2$ in some genes, as demonstrated by \textit{int} SGA, which could lead to the generation of PCR artifacts.

To understand the potential impact of the SI on the host immune system, we analyzed alterations during the follow-up period in the frequencies of the T cell subsets and immune response to HIV peptides in PBMC samples collected at V3$_{2010}$ (prior to SI), V4$_{2011}$ (at the moment of B2 \textit{env} variant identification after SI onset), V7$_{2013}$ (prior to the first peak of viremia), V9$_{2014}$ (at the first peak of viremia and detection of B$_1$ and B$_2$ \textit{env} and \textit{int} variants), V14$_{2016}$ (after viremia control) and V16$_{2017}$ (at the second peak of viremia). Briefly, T cell activation was evaluated by multiparametric flow cytometry by staining the cells with anti-CD3, anti-CD4 or anti-CD8, anti-CD38 and anti-HLA-DR antibodies to determine the frequencies of CD38$^+$HLA-DR$^+$ cells in both CD4$^+$ and CD8$^+$ subsets, as previously described [22]. In addition, cells were also labeled with anti-CD45RA, anti-CD27 and anti-CD95 antibodies to evaluate the frequencies of naïve (TN; CD45RA$^+$CD27$^+$CD95$^-$), system memory (TSCM; CD45RA$^+$CD27$^+$CD95$^+$), central memory (TCM; CD45RA$^-$CD27$^+$CD95$^+$), effector memory (TEM; CD45RA$^-$CD27$^+$CD95$^+$) and effector (TEFF; CD45RA$^+$CD27$^+$CD95$^+$) T cell subsets.

An increase in the percentage of CD8$^+$CD38$^+$HLA-DR$^+$ T cells was observed in samples from V3$_{2010}$ (6.81%) to V9$_{2014}$ (14%), followed by a decrease at V14$_{2016}$ (6.76%) and a new peak at V16$_{2017}$ (14.40%) (Fig. 4a). This higher values in the V4$_{2011}$ sample than in the V3$_{2010}$ sample, despite the lower plasmatic viral load, could be suggestive of an association between the SI event and an increase in immune activation. After the

---

**Fig. 3** Longitudinal analysis of proviral HIV-1 integrase sequences obtained from VC06 during 2011 and 2014. Sequence names are colored according to their respective visit, clusters containing B$_1$ and B$_2$ sequences are shaded in blue and red, respectively, and the total number of sequences and proportion of B$_1$ and B$_2$ variants are indicated on the stacked bar graph, as previously described. Int sequence obtained from B$_1$ full length genome is included to confirm B$_1$ cluster identity. The tree was constructed using the Tamura Nei model and 1000 bootstrap replicates in MEGA 6 software. Bootstrap values lower than 75% are not shown. Reference sequences for HIV-1 subtypes D, F, and B were used as an outgroup and are shown in black.
emergence of B, the percentage of CD8⁺CD38⁺HLA-DR⁺ T cells followed plasmatic viral load levels, highlighting the relationship between the antigen viral load and CD8⁺ T cell activation. Although at more discrete levels, the same trend was also observed for CD4⁺ T cells (Fig. 4a). In relation to the CD4⁺ T cell subsets (Fig. 4b), we observed a decrease in the frequency of TCM cells between the V4 2011 and V14 2016 samples, with the recovery of those cells in the V16 2017 sample and an inverse pattern observed for TTM cells. The frequency of CD4⁺ TEM cells reached the highest levels at visits near the detection of the superinfection (V4 2011) and at both peaks of viremia (V9 2014 and V16 2017). For CD8⁺ subsets (Fig. 4c), the frequency of TEM and TEFF cells followed the viral load dynamics, which was in contrast with the expected TN cells expansion after the first viral load peak. Despite these variations, no statistical correlations between the frequencies of the different T cell subsets and plasmatic viral load were found during the follow-up.

In addition, we used Gag and Nef HIV-1 peptides matching CTL epitopes, based on the VC06 HLA-B genotype, to evaluate the HIV-specific T cell response by IFN-γ ELISpot assay and intracellular cytokine and CD107 staining. In general, very low or undetectable HIV-1-specific responses were observed, with the exception of the V9 2014 sample, when approximately 1% of CD107⁺CD8⁺ T cells showed detectable Gag- or Nef-specific responses (data not shown). No pattern of increase/decrease in the cytokine response was observed in consequence of the antigenic stimulation related to the viral load peak.

Discussion and conclusions

Here, we report the case of a transgender HIC who experienced a partial loss of viremia control after HIV-1 intrasubtype SI with another subtype B variant. Through molecular analyses of the HIV-1 env gene during clinical follow-up, we were able to trace the SI to some time between mid-2010 and mid-2011. At the time, VC06 already had 10 years of diagnosed HIV-1 infection with consistently low viremia and high counts of CD4⁺ T cells in the absence of antiretroviral therapy. This finding indicates that despite natural protection against disease progression, HICs can still be at risk for subsequent infections with new variants, reinforcing the need for continued use of prevention strategies.

The mechanisms underlying viremia and disease progression control phenotypes are not yet fully understood. Studies have shown that they could be associated with host genetic background [23–25], virological characteristics [26, 27], and low levels of immune activation and preservation of memory T cells, among other immunological aspects [28]. CCR5 genetic analysis of the VC06 patient identified heterozygosity for the Δ32 allele (CCR5wild type/CCR5Δ32), a mutated allele previously associated with protection against infection when presented in homozygosis and that has a partial protective role or delayed AIDS progression in heterozygosis [29–33]. However, the association of this genetic characteristic
with the of HIV pathogenesis and superinfection could not be established in the present case study.

Although the existence of X4-tropic variants after the superinfection could explain the loss of viremia control in this context, our tropism analyses identified only R5-tropic quasispecies. Despite phenotypic analyses for tropism characterization were not realized, the genotypic analysis in geno2pheno tool had been previously showed to be highly concordant when compared to in vitro assays [34–37]. Moreover, most of the sequences presented high FPR values and lower FPR values were found only in a few sequences representing minoritary variants that should not have a great impact on disease progression or viremia. In the whole, although we can not rule out completely, it is very unlikely that loss of control in VC06 might be associated with the onset of an X4-tropic virus after superinfection. In addition to the VC06 genetic background described in the present study, the diversity of protective elements described in the literature suggest that the control phenotype is not determined by a single factor but is rather probably a result of a set of host and virus characteristics acting synergistically.

Only a few studies are available in the literature with cases of SI in HICs or LTNP. For some of those studies, SI was associated with disease progression in HICs soon after reinfection [14, 15, 38, 39], as previously observed for noncontrollers [8–10]. However, other studies showed that HICs are able to maintain high CD4+ T cell counts and plasmatic viral load at low or undetectable levels after SI [11–13, 18, 40, 41]. This sustained progression control, however, seems to have some complexity, as some of those individuals maintain stable CD4+ T cell counts despite experiencing transient viremia incompatible with a previous clinical history [11–13, 18, 40, 41]. The data presented in this study, along with those previously published, reaffirm the complexity of the control phenotype and show that a previous control profile of a single variant does not guarantee immediate and/or efficient control of subsequent infections.

Despite reinfection at the end of 2010, VC06 only started to present increasing viremia at the beginning of 2013, with a peak of 10,000 copies/ml 1 year later. In some cases, the HIC phenotype is the result of infection with defective or attenuated viral strains [42–44]. Previously, Braibant et al. [14] demonstrated the case of an elite controller previously infected with a defective virus who presented disease progression after SI with a competent HIV-1 variant. In our study, the lack of genetic defects in the B1 complete genome sequence indicates that B1 is a replication-competent virus, and the partial viremia control and the absence of disease progression after entry of the second variant pointed to an inherent and differential ability of the VC06 immune system to control HIV infection, compatible with the HIC phenotype.

The delay in viremia increase also indicates that the loss of viremia control was related to some evolutionary dynamics of both the B1 and B2 variants and not only to the entry of a new virus. Part of this dynamic could be related to recombination processes occurring between the B1 and B2 variants. Recombination is an important mechanism of diversity generation and immune escape [45] observed in many cases of SI [14, 38, 46–48], including in some HICs who developed disease progression [14, 38]. The frequency discrepancy for B1-related int vs env sequences via SGA suggested the presence of recombinant B1B2. Although a PCR bias could also explain this difference, a variation of more than 30% in the representativity between the two fragments is less likely to occur due to PCR efficiency. In addition, the sample dilution prior to PCR, that is characteristic of the SGA methodology, should soften the template competition. Albeit this indicates that the differences observed are really due to a variation at the balance between B1 and B2 variants in int vs env, our analyses did not observed a recombination point in int.

Another sign of the importance of evolutionary dynamics for the clinical consequences of SI for VC06 was the observation of different B2 env clusters associated with both the V9_2014 and V16_2017 samples plus the increase of viral divergence between 2011 and 2017. These data also support the hypothesis that partial loss of viremia control is related to the escape of specific viral populations from the immune response.

The pattern of increase or decrease in the percentage of CD38+HLA-DR+ T cells following alterations in the plasmatic viral load also points toward the participation of the immune response in the management of the infection during follow-up. T cell subset analyses showed an increase in the proportion of T cells with an effector phenotype (TEM and TEFF) at the timepoints close to SI and of increased viremia, suggesting a possible role for these cells in controlling viral replication. Although no expressive alterations in the Gag and Nef HIV-specific responses were observed during follow-up, this result did not exclude the presence of an HIV-specific immune response to regions other than those analyzed by us.

Finally, it is important to highlight that VC06 continued to maintain high and stable CD4+ T cell counts despite the partial loss of viremia control. These data support that virological and immunological control are not necessarily concomitant. Together with other studies that described superinfected HICs with no alterations in CD4+ T cell counts but a loss of viremia control [11–13, 18, 40, 41], our data indicate that moderate viremia, in some cases, is not able to impair immunological control.
Despite the partial loss of viremia control and the policy of the Brazilian Ministry of Health indicating antiretroviral treatment to all HIV-infected individuals, VC06 refused to initiate cART. The knowledge of her HIC status and the maintenance of immunological control together with side effects observed during a short period of cART were motivations for this refusal. This patient has been followed-up every 6 months to assess her immunological, clinical and virological status, and no signal of disease progression has been detected thus far. At all clinical visits, cART has again been offered.

Overall, this case raises awareness of the need for continued use of adequate preventive strategies after HIV-1 infection, even in patients with a long history of viremia control and an absence of disease progression. For HICs, our data demonstrate that natural control of HIV-1 replication can be a labile state since the underlying mechanisms associated with this phenotype do not guarantee unrestricted control of any other variant. More studies identifying the factors associated with control of multiple variants in HICs can be an important pathway to identify factors associated with natural control.

Abbreviations
cART: Combination antiretroviral therapy; CTL: Cytotoxic T Lymphocyte; DI: Dual-infection; env: env gene; HICs: HIV controllers; int: integrase gene; LTNP: Long-term non-progression; PBMC: Peripheral blood mononuclear cells; SGA: Single genome amplification; SI: Superinfection; TCM: Central-memory T cell; TEFF: Effector T cell; TEM: Effector-memory T cell; TN: Naïve T cell; TPHA: Treponema pallidum hemagglutination assay; TSCM: Stem-memory T cell; VDRL: Venereal disease research laboratory test

Acknowledgments
We thank the patient, nurses, and clinicians who participated in the study. We also thank Mr. Egydio Sampaio for supporting in the recruitment of patients and all INI staff from the blood collection sector. We also acknowledge the Fiocruz Technologic Platforms Network RPT08A (Flow Cytometry facility) and RPT08C (ELIspot facility). Finally, we thank the CD4+ T cell counts and HIV-1 viral load clinical services.

Authors' contributions
DGC conducted most of the experiments and analyzed the data. SSDdA conducted part of the SGA experiments and prepared plasma sequences. GB, FHC, MGM and MLG supervised the experiments and gave intellectual input. LMW, BH, BG, and VGV conducted patient recruitment and follow-up. DGC, MGM, and FHC wrote the first draft. All authors revised and approved the final manuscript.

Funding
This work was supported by the Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro – FAPERJ; Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq; and Fundação Oswaldo Cruz – FIOCRUZ. None of these cited academic research funding institutions had participation in the design of the study, collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
HIV-1 env sequences generated from V4201 sample were previously deposited in GenBank under the accession numbers KY852775-KY852806. The remaining sequences generated during the current study were deposited in GenBank under the accession numbers MK75267-MK757421.

Ethics approval and consent to participate
The present work was approved by the Brazilian National Human Research Ethics Committee (CONEP 840/2008) and by the FIOCRUZ Research Ethics Committee (CEP 1717.0.000.009–07). The studied subject gave written informed consent for the use of biological samples.

Consent for publication
The studied subject gave written informed consent for publication of the results showed in this study.

Competing interests
The authors declare that they have no competing interests.

Author details
1Laboratório de Aids e Imunologia Molecular, Instituto Oswaldo Cruz (IOC) – FIOCRUZ, Av. Brasil 4365, Rio de Janeiro, RJ 21045-900, Brazil. 2Instituto Nacional de Infectologia Evandro Chagas (INI), Laboratório de Pesquisa clínica em DST e Aids, Rio de Janeiro, Brazil.

Received: 10 April 2019 Accepted: 26 June 2019
Published online: 05 July 2019

References
1. Okulicz JF. Elite controllers and long-term nonprogressors: models for HIV vaccine development? J AIDS Clin Res. 2012;03:139.
2. van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology. 2007;4:57.
3. Andreani G, Espada C, Caballos A, Ambrosioni J, Petroni A, Pugliese D, et al. Detection of HIV-1 dual infections in highly exposed treated patients. Virol. 2011;8:392.
4. Soares de Oliveira AC, Pessôa de Farias R, da Costa AC, Sauer MM, Bassichetto KC, Oliveira SMS, et al. Frequency of subtype B and F1 dual infection in HIV-1 positive, Brazilian men who have sex with men. Virol. 2011;29:223.
5. Rendl AD, Serrwanda D, Vendeite J, Wendel SK, Ndemi N, Bukeyna J, et al. Rates of HIV-1 superinfection and primary HIV-1 infection are similar in female sex workers in Uganda. AIDS. 2014;28:2147–52.
6. Wagner GA, Pacold ME, Kosakovsky Pond SL, Caballero G, Chaillon A, Rudolph AE, et al. Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis. 2014;209:1032–8.
7. Leye N, Vidal N, Ndiaye O, Diao-Ndiaye H, Wade AS, Mboup S, et al. High frequency of HIV-1 infections with multiple HIV-1 strains in men having sex with men (MSM) in Senegal. Infect Genet Evol. 2013;20:206–14.
8. Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Groblier J, Li F, et al. Dual HIV-1 infection associated with rapid disease progression. Lancet. 2004;363:619–22.
9. Luan H, Han X, Yu X, An M, Zhang H, Zhao B, et al. Dual infection contributes to rapid disease progression in men who have sex with men in China. J Acquir Immune Defic Syndr. 2017;75:480–7.
10. Cornelissen M, Pasternak AO, Grinjen ML, Zorgdrager F, Bakker M, Blom P, et al. HIV-1 dual infection is associated with faster CD4+ T-cell decline in a cohort of men with primary HIV infection. Clin Infect Dis. 2012;54:339–47.
11. Pernas M, Casado S, Sandonis V, Arcones C, Rodríguez C, Ruiz-Mateos E, et al. Prevalence of HIV-1 dual infection in long-term nonprogressor-elite controllers. J Acquir Immune Defic Syndr. 2013;64:225–31.
12. Casado S, Pernas M, Alvaro T, Sandonis V, García S, Rodríguez C, et al. Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease. J Infect Dis. 2007;196:895–9.
13. Rachinger A, Navis M, van Assen S, Groeneveld PHP, Schuitemaker H. Recovery of virological control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin Infect Dis. 2008;47:e86–9.
14. Brabant M, Xie J, Samiri A, Agut H, Autran B, Barn F. Disease progression due to dual infection in an HLA-B57-positive asymptomatic long-term nonprogressor infected with a nef-defective HIV-1 strain. Virology. 2010;405:81–92.
15. Cleve O, Colombo S, Verly S, Teleni A, Cavassini M. HIV-1 elite controllers: beware of super-infections. J Clin Virol. 2010;47:376–8.
16. Caetano DG, Côrtes FH, Bello G, Teixeira SLM, Hoagland B, Grinsztejn B, et al. Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control. Retrovirology. 2018;15:62.
17. Sharkey M, Babic DZ, Greenough T, Gulick R, Kurtzkes DR, Stevenson M. Epidural viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011;7:e1001303.

18. de Azevedo SSD, Delatorre E, Córtes FH, Hoagland B, Grinstejn B, Veloso VG, et al. HIV controllers suppress viral replication and evolution and prevent disease progression following intersubtype HIV-1 superinfection. AIDS. 2019;33(3):399–410.

19. Lengauer T, Sander O, Sienna S, Thilen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol. 2007;25:1407–10.

20. Felsenstein J. PHYLIP (Phylogeny inference package) version 3.6. Distributed by the author; 2008.

21. da Reis NGS, Bello G, Guimardes ML, Stefani MMA. Characterization of HIV-1 CRF90_BF1 and putative novel CRFs_BF1 in central west, north and northeast Brazilian regions. PLoS One. 2017;12:e017858.

22. de Paula HHS, Ferreira ACG, Caetano DG, Delatorre E, Teixeira SL, Coelho LE, et al. Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection. Retrovirology. 2018;15:71.

23. Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;2:405–11.

24. Hendel H, Callai-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162:6942–6.

25. Alfieri M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS. 2003;17:2581–91.

26. Rodés B, Toro C, Pivónos E, Poveda E, Martínez-Padial M, Benito JM, et al. Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS. 2004;18:1109–16.

27. Kitchhoff F, Easterbrook PJ, Douglas N, Troop M, Greenough TC, Weber J, et al. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol. 1999;73:4997–508.

28. Sáez-Cirión A, Pancino G. HIV controllers: a genetically determined or inducible phenotype? Immunol Rev. 2013;254:281–94.

29. Philpott S, Weiser B, Tarwater P, Vermund SH, Smith G, Kleeberger CA, Gange SJ, et al. Sequence variations in human immunodeficiency virus type 1 nef are associated with different stages of disease. J Virol. 1999;73:4997–508.

30. Sánchez-Cirión A, Pancino G. HIV controllers: a genetically determined or inducible phenotype? Immunol Rev. 2013;254:281–94.

31. Oh D-Y, Jensen H, Kücherer C, Neumann K, Oh N, Poggensee G, et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta2 homozygous individual. PLoS One. 2008;3:e2747.

32. Samson M, Liberti F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722–5.

33. Estrada-Aguirre JA, Cáceres-Salazar SG, Ochoa-Ramírez LA, de Acosta-Cota SJ, Zamar-Gómez R, Navar-Reyes GM, et al. Protective effect of CCR5-Delta32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther. 2006;3:22.

34. Oh D-Y, Jensen H, Kücherer C, Neumann K, Oh N, Poggensee G, et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta2 homozygous individual. PLoS One. 2008;3:e2747.

35. Samson M, Liberti F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722–5.

36. Estrada-Aguirre JA, Cáceres-Salazar SG, Ochoa-Ramírez LA, de Acosta-Cota SJ, Zamar-Gómez R, Navar-Reyes GM, et al. Protective effect of CCR5-Delta32 allele against HIV-1 in Mexican women. Curr HIV Res. 2013;11:506–10.

37. Kagan RM, Johnson EP, Shaw MF, Van Baelen B, Ogden R, Platt JL, et al. Comparison of genotypic and phenotypic HIV type 1 tropism assay results from the screening samples of cencriviruc study 202, a randomized phase II trial in treatment-naïve subjects. AIDS Res Hum Retrovir. 2013;30:1511–9.

38. Torres AJL, de Macedo Brígido LF, Abrahão MHN, Angelo ALD, de Jesus Ferreira G, Coelho LP, et al. High degree of concordance between flow cytometry and geno2pheno methods for HIV-1 tropism determination in proviral DNA. Braz J Infect Dis. 2015;19:163–5.

39. Brener J, Gall A, Hurst J, Batorsky R, Lavandier N, Chen F, et al. Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient. Retrovirology. 2018;15:7.

40. Pernas M, Casado C, Arcones C, Llano A, Sánchez-Merino V, Mothe B, et al. Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfection HIV-1 LTNP elite controller. PLoS One. 2012;7:e31928.

41. Rossás-Umbert M, Llano A, Bellido R, Olivera A, Ruiz-Rioll M, Rocafort M, et al. Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers. J Virol. 2018;92:e01436.

42. Salvi R, Garbuglia AR, Di Caro A, Pulciani S, Montella F, Benedetto A. Gravidity and perinatal coreceptor usage in a cohort of Italian HIV-1 infected pregnant women. J Retrovirology. 2012;5:30.

43. Michael NL, Chang G, D’Arcy LA, Ehrenberg PK, Mariani R, Busch MP, et al. Protective effect of the CCR5 Delta-32 allele on the risk of HIV-1 transmission among men who have sex with men. AIDS Res Hum Retrovir. 2013;30:963–70.

44. Ritchie A, Cai F, Smith N, Chen S, Song H, Brackenridge S, et al. Recombination-mediated escape from primary CCR5+ T cells in acute HIV-1 infection. Retrovirology. 2014;11:69.

45. Koning F, Badhan A, Shaw S, Fisher M, Mbiase JL, Cane PA. Dynamics of HIV type 1 recombination following superinfection. AIDS Res Hum Retrovir. 2013;30:963–70.

46. Chaillon A, Wagner GA, Hepler NL, Little SJ, Kosakovsky Pond SL, Caballero G, et al. Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection. J Virol. 2013;87:12737–44.

47. Blackard JT, Mayer KH. HIV superinfection in the era of increased sexual risk-taking. Sex Transm Dis. 2004;31:201–4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: with 100M website views per year

At BMC, research is always in progress.
Learn more at biomedcentral.com/submissions